Latest market price
70.67
-1.33-1.85%
OverviewShort InterestFilings
ANIPQT46ANI Pharmaceuticals, Inc.·NASDAQ
70.67-1.85%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
ALVO-3.66%$4.48PAHC-0.36%$38.74ETON-2.63%$50.81PCRX+0.03%$36.40TRLV+7.98%$11.10CRON+0.91%$3.33PRGO-0.19%$15.75AMPH-2.49%$27.03
Snapshot
Index—P/E15.26EPS (ttm)4.63Insider Own24.02%Shs Outstand22.96MPerf Week-2.66%
Market Cap1.62BForward P/E6.98EPS next Y10.13Insider Trans-2.15%Shs Float19.67MPerf Month-2.09%
Enterprise Value1.58BPEG1.64EPS next Q2.18Short Float17.65%Perf Quarter-10.77%
Income105.00MP/S1.66EPS this Y22.91%Short Ratio9.13Perf Half Y-14.15%
Sales978.00MP/B2.72EPS next Y9.31%ROA7.08%Short Interest3.47MPerf YTD-10.48%
Book/sh26.00P/C4.32EPS next 5Y9.29%ROE19.19%52W High95.57 -26.05%Perf Year-23.13%
Cash/sh16.38P/FCF10.14EPS past 3/5Y—ROIC9.26%52W Low69.58 1.57%Perf 3Y16.85%
Dividend Est.—EV/EBITDA6.18Sales past 3/5Y40.85% 33.53%Gross Margin65.23%Volatility2.66% 2.63%Perf 5Y85.58%
Dividend TTM—EV/Sales1.61EPS Y/Y TTM—Oper. Margin15.35%ATR (14)2.03Perf 10Y6.54%
Dividend Ex-Date—Quick Ratio2.41Sales Y/Y TTM30.92%Profit Margin10.82%RSI (14)42.59Recom2.40
Dividend Gr. 3/5Y—Current Ratio2.91EPS Q/Q22.78%SMA20-2.09%Beta0.47Target Price99.50
Payout0.33%Debt/Eq0.55Sales Q/Q26.07%SMA50-3.01%Rel Volume1.30Prev Close72.00
Employees970LT Debt/Eq0.52EarningsNov 05SMA200-8.91%Avg Volume390.83KPrice70.67
IPO DateMay 05, 2000Option/ShortYes / YesEPS/Sales Surpr.8.19% 2.27%Net Debt/EBITDA-0.18Volume509,999Change-1.85%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-23-26InitiatedOppenheimerPerform$85
Sep-09-26InitiatedLeerinkOutperform$104
Aug-10-26ReiteratedGuggenheimBuy$124 → $119
Aug-10-26ReiteratedCanaccord GenuityHold$91 → $90
Jul-16-26InitiatedCanaccordHold$91
Jan-16-26ReiteratedGuggenheimBuy$114 → $124
Oct-09-25ReiteratedTruist SecuritiesHold$60 → $90
Sep-17-25ReiteratedHC Wainwright & Co.Buy$94 → $121
Sep-08-25ReiteratedGuggenheimBuy$86 → $114
Aug-08-25ReiteratedPiper Sandler$80 → $94
Latest News· Times ET
Today
Today06:55AM
ANI Pharmaceuticals to Present at Upcoming November Investor Conferencesglobenewswire.com
Oct-29-26
Oct-29-2607:35AM
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue EstimatesYahoo
Oct-23-26
Oct-23-2606:55AM
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ETglobenewswire.com
Oct-19-26
Oct-19-2606:55AM
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsulesglobenewswire.com
04:22AM
ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $388,206.00 in Stockdefenseworld.net
02:57AM
ANI Pharmaceuticals Launches Duloxetine Delayed-Release Capsules 20, 30 And 60 Mg, Generic Version Of Reference Listed Drug CymbaltaBenzinga
Oct-13-26
Oct-13-2601:10PM
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?zacks.com
09:56AM
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radarzacks.com
Oct-07-26
Oct-07-2606:13PM
Did FDA Approval of Generic Everolimus Suspension Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?Yahoo
Oct-06-26
Oct-06-2608:14AM
Head to Head Comparison: ANI Pharmaceuticals (NASDAQ:ANIP) and Talphera (NASDAQ:TLPH)defenseworld.net
Oct-01-26
Oct-01-2608:13AM
1 Small-Cap Stock for Long-Term Investors and 2 We IgnoreYahoo
Sep-30-26
Sep-30-2606:55AM
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meetingglobenewswire.com
Sep-28-26
Sep-28-2612:46PM
Implied Volatility Surging for ANI Pharmaceuticals Stock Optionszacks.com
Sep-24-26
Sep-24-2612:15PM
ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Buildseekingalpha.com
Sep-23-26
Sep-23-2606:55AM
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspensionglobenewswire.com
Company

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue978883614487—————
Cost of Goods Sold Incl. D&A341433250182—————
Gross Profit639451364305—————
Selling, General and Administrative Excl. Other326318250162—————
Research and Development50524534—————
Other Operating Expense111-16962—————
Operating Income15081147—————
Interest Expense28201827—————
Unusual Expense
—————————
Non-Operating Income (Expense)2035-50—————
Net Income Before Taxes14296-2220—————
Income Taxes3417-41—————
Consolidated Net Income10578-1919—————
Net Income From Continuing Operations10878-1919—————
Net Income10578-1919—————
EPS (Recurring)4.833.50-1.040.95—————
EPS (Basic, Before Extraordinaries)4.833.50-1.040.95—————
EPS (Diluted)4.633.32-1.040.94—————
EBITDA25520763107—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio15.2623.78—58.66—————
Price To Sales Ratio1.521.791.712.04—————
Gross Margin65.3451.0859.2862.63—————
Operating Margin15.349.170.169.65—————
Net Margin10.748.83-3.093.90—————
Shares Outstanding21201918—————
Market Capitalization1,4841,5791,050993—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$103.11$93.80$84.48$75.17$65.86● Close Price0.00M1.42M2.84M4.27M5.69MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
CAREY STEPHEN P.SVP & CFOOct 29 '26Sale72.872,850207,680166,143Oct 30
Lalwani NikhilPRESIDENT & CEOOct 15 '26Sale71.895,400388,206333,689Oct 16
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Oct 13 '26Sale73.5950036,79573,424Oct 13
CAREY STEPHEN P.SVP & CFOSep 29 '26Sale73.002,850208,050168,993Sep 30
Lalwani NikhilPRESIDENT & CEOSep 15 '26Sale71.005,400383,400339,089Sep 16
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Sep 14 '26Sale70.7950035,39573,924Sep 14
Thoma JeanneDirectorSep 11 '26Sale71.531,00071,53026,762Sep 14
CAREY STEPHEN P.SVP & CFOAug 31 '26Sale72.802,850207,480171,843Sep 01
Lalwani NikhilPRESIDENT & CEOAug 25 '26Sale74.305,400401,220344,489Aug 26
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Aug 13 '26Sale75.4850037,74074,424Aug 13
Gutwerg OriSVP, GENERICSAug 10 '26Sale77.003,162243,47475,534Aug 11
CAREY STEPHEN P.SVP & CFOJul 29 '26Sale81.362,850231,876174,693Jul 30
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Jul 13 '26Sale81.8450040,92077,390Jul 14
CAREY STEPHEN P.SVP & CFOJul 02 '26Option Exercise49.513,313164,027180,856Jul 06
CAREY STEPHEN P.SVP & CFOJul 02 '26Sale86.003,313284,918177,543Jul 06
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.